A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT07452198 · RECRUITING
Trial details
- NCT number
- NCT07452198
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-09
- Primary completion
- 2029-03-01
- Enrollment
- 358
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.